Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Boehringer
Ingelheim in the ethical pharma sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Boehringer Ingelheim' s performance against key rivals in the
ethical pharmaceutical sector
- Analyze how the asthma and COPD therapy Spiriva will act as the key driver
of Boehringer Ingelheim' s commercial performance out to 2012
- Assess Boehringer Ingelheim' s narrow therapeutic focus and the potential
barrier to sales growth that this will provide
View Cart
